Holen Sie sich die Stockscreener-App
1.76
7.98%
0.13
Handel nachbörslich:
1.76
Schlusskurs vom Vortag:
$1.63
Offen:
$1.64
24-Stunden-Volumen:
606.85K
Relative Volume:
0.68
Marktkapitalisierung:
$83.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-123.46M
KGV:
-0.6771
EPS:
-2.5993
Netto-Cashflow:
$-104.11M
1W Leistung:
+6.02%
1M Leistung:
-0.56%
6M Leistung:
-48.84%
1J Leistung:
+3.53%
1-Tages-Spanne:
$1.61
$1.76
1-Wochen-Bereich:
$1.55
$1.76
52-Wochen-Spanne:
$1.14
$4.02
Bioatla Inc Stock (BCAB) Company Profile
Firmenname
Bioatla Inc
Sektor
Branche
Telefon
858-558-0708
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-09-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-05-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | BTIG Research | Buy |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-01-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
BioAtla Inc (BCAB)’s financial ratios: A comprehensive overview - The Dwinnex
A new trading data show BioAtla Inc (BCAB) is showing positive returns. - SETE News
XTX Topco Ltd Trims Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Scion Asset Management LLC Purchases Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Wall Street SWOT: BioAtla stockInnovative cancer therapy faces pivotal year - Investing.com
BCAB’s valuation metrics: A comprehensive analysis - US Post News
Scion Asset Management LLC Purchases Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
Century Therapeutics (NASDAQ:IPSC) & BioAtla (NASDAQ:BCAB) Financial Comparison - Defense World
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development - MSN
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development - MyChesCo
Analyzing Bio-Techne Corp (TECH) After Recent Trading Activity - Knox Daily
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Saba Capital Management, L.P. Sells 33,209 Shares - Defense World
BioAtla out-licenses T cell therapy in $134 million deal - The Pharma Letter
(BTMD) Technical Pivots with Risk Controls - Stock Traders Daily
BioAtla licenses cancer drug candidate to Context Therapeutics By Investing.com - Investing.com Canada
BioAtla licenses cancer drug candidate to Context Therapeutics - Investing.com
Dawson James downgrades BioCardia Inc. (BCDA) stock to a Neutral - Knox Daily
Context Therapeutics signs second multimillion-dollar licensing deal in 3 months - The Business Journals
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Sells $245,706.93 in Stock - Defense World
SickKids names FCB Canada new AOR - Strategy Online
Context builds up bank of bispecific antibodies with up to $133M biobucks deal for BioAtla asset - Fierce Biotech
BioAtla licenses cancer drug candidate to Context Therapeutics - Investing.com India
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody - GlobeNewswire
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody - StockTitan
Massachusetts Financial Services Co. MA Has $741,000 Holdings in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Acadian Asset Management LLC Sells 80,157 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Benjamin Edwards Inc. Decreases Stake in Bank of America Co. (NYSE:BAC) - MarketBeat
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Saba Capital Management, L.P. Sells 15,894 Shares - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 6.3% in August - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 6.3% in August - MarketBeat
Analyzing Genocea Biosciences (NASDAQ:GNCA) and BioAtla (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Stock Rating Reaffirmed by JMP Securities - Defense World
Balance Sheet Insights: BioAtla Inc (BCAB)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
BCAB’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
BioAtla reports promising Phase 2 trial results for cancer drug By Investing.com - Investing.com Canada
Head to Head Contrast: Genocea Biosciences (NASDAQ:GNCA) vs. BioAtla (NASDAQ:BCAB) - Defense World
BioAtla reports promising Phase 2 trial results for cancer drug - Investing.com
BioAtla reports promising Phase 2 trial results for cancer drug By Investing.com - Investing.com UK
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 Euro - Yahoo Finance
JMP Securities Reiterates Market Outperform Rating for BioAtla (NASDAQ:BCAB) - MarketBeat
Examining BioAtla Inc (BCAB) more closely is necessary - US Post News
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting - StockTitan
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting - Yahoo Finance
BioAtla Inc (BCAB) Stock: Navigating Drops and Gains - The InvestChronicle
Should investors be concerned about BioAtla Inc (BCAB)? - US Post News
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky - Yahoo Finance
Daily Market Movement: BioAtla Inc (BCAB) Sees a -2.75 Decrease, Closing at 1.77 - The Dwinnex
Short Interest in BioAtla, Inc. (NASDAQ:BCAB) Rises By 18.8% - MarketBeat
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Stocks of BioAtla Inc (BCAB) are poised to climb above their peers - SETE News
Financial Fitness Check: Examining BioAtla Inc (BCAB)’s Key Ratios - The Dwinnex
Finanzdaten der Bioatla Inc-Aktie (BCAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
4.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):